Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Special Populations Head-to-Head

What These Two Drugs Actually Do

Zoledronic acid and romosozumab work through entirely different mechanisms, which is why comparing them requires looking at the patient, not just the drug label.

Zoledronic acid is a third-generation nitrogen-containing bisphosphonate. It inhibits farnesyl pyrophosphate synthase in osteoclasts, suppressing bone resorption and preserving existing bone mass [1]. A single 5 mg annual infusion produces clinically meaningful suppression of bone turnover markers within days and sustains that suppression for 12 months.

Romosozumab inhibits sclerostin, a glycoprotein produced by osteocytes that normally brakes bone formation. Blocking sclerostin simultaneously increases bone formation and decreases resorption, a dual effect no bisphosphonate replicates [2]. This anabolic window closes after 12 months, which is why the drug is licensed only for one year of treatment.

Mechanism Summary

| Property | Zoledronic Acid (Reclast) | Romosozumab (Evenity) | |---|---|---| | Mechanism | Osteoclast inhibition | Sclerostin inhibition (dual action) | | Route | IV infusion | Subcutaneous injection | | Frequency | Once yearly | Monthly x 12 months | | Duration of therapy | 3 to 6 years typical | 12 months, then sequential therapy | | Black box warning | Atypical femur, osteonecrosis | Cardiovascular events (MI, stroke) | | FDA approval year | 2007 | 2019 |

Key Trial Results: HORIZON-PFT vs ARCH

HORIZON-PFT (Zoledronic Acid)

HORIZON-PFT enrolled 7,765 postmenopausal women with osteoporosis and randomized them to zoledronic acid 5 mg IV or placebo once yearly for 3 years. Published in the New England England Journal of Medicine in 2007, the trial showed a 70% reduction in morphometric vertebral fractures, a 41% reduction in hip fractures, and a 25% reduction in nonvertebral fractures compared with placebo [1]. All-cause mortality fell by 28% in a post-hip-fracture extension sub-study. Those numbers established zoledronic acid as a first-line standard of care.

ARCH (Romosozumab vs Alendronate)

The ARCH trial (N=4,093) compared 12 months of romosozumab 210 mg monthly followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis and a prior vertebral fracture. At 24 months, the romosozumab-then-alendronate sequence reduced new vertebral fractures by 48%, clinical fractures by 27%, and nonvertebral fractures by 19% compared with alendronate alone [3]. Hip fractures fell by 38% in the romosozumab sequence arm.

The ARCH trial also flagged the cardiovascular signal: serious cardiac events occurred in 2.5% of the romosozumab group versus 1.9% of the alendronate group during the 12-month anabolic phase, which drove the FDA boxed warning [3].

No Direct Zoledronic Acid vs Romosozumab Head-to-Head Randomized Controlled Trial Exists

This is a key clinical reality. Physicians and patients rely on indirect comparisons, network meta-analyses, and observational data. A 2022 network meta-analysis in the Journal of Bone and Mineral Research placed romosozumab at the top of the fracture-reduction hierarchy for vertebral outcomes, with zoledronic acid performing strongly for both vertebral and hip endpoints [4]. Direct randomization between the two has not been completed as of mid-2025.

Postmenopausal Women: The Core Population

Both drugs carry FDA approval for postmenopausal osteoporosis. The choice depends on fracture history, T-score, and cardiovascular profile.

Very High Fracture Risk

The American Association of Clinical Endocrinology (AACE) 2020 guidelines define "very high risk" as a T-score below negative 3.0, recent fracture (within 12 months), or a FRAX 10-year hip fracture probability above 4.5% with prior fracture [5]. For these patients, AACE recommends starting with an anabolic agent. Romosozumab fits this category directly; zoledronic acid does not carry anabolic action.

A 2021 observational cohort study (N=812) published in the Journal of Clinical Endocrinology and Metabolism found that women switching from an oral bisphosphonate to romosozumab gained 9.8% lumbar spine BMD at 12 months, significantly greater than the 3.1% seen in matched patients continuing zoledronic acid [6].

Standard High Risk

For postmenopausal women at high (not very high) risk without recent fracture and without cardiovascular contraindications, zoledronic acid remains an excellent first-line option. Annual dosing improves adherence over oral bisphosphonates, and generic availability reduces cost substantially [1].

Men with Osteoporosis

Zoledronic Acid in Men

HORIZON-Recurrent Fracture Trial extended zoledronic acid data to men with recent hip fracture. Zoledronic acid reduced subsequent clinical fractures by 35% and mortality by 28% compared with placebo, though the trial was not powered exclusively for a male subgroup [7]. The FDA approved zoledronic acid for osteoporosis in men in 2007.

Romosozumab in Men

The BRIDGE trial (N=245) evaluated romosozumab 210 mg monthly for 12 months in men with osteoporosis. Lumbar spine BMD increased by 12.1% versus 1.0% for placebo at 12 months [8]. Total hip BMD rose 2.5% versus 0.5% for placebo. The FDA approved romosozumab for men at high fracture risk in 2019 [2].

No head-to-head fracture endpoint trial in men exists for either drug against the other. Clinicians choosing between them for male patients must extrapolate from BMD surrogate data and the indirect comparison literature.

Glucocorticoid-Induced Osteoporosis (GIOP)

Why GIOP Is a Special Case

Glucocorticoids suppress bone formation directly and increase resorption through multiple pathways, including osteoblast apoptosis and increased RANKL expression [9]. The resulting bone loss can be rapid, studies show up to 6 to 12% spinal BMD loss in the first year of high-dose glucocorticoid use [9].

Zoledronic Acid in GIOP

The American College of Rheumatology (ACR) 2022 GIOP guidelines recommend zoledronic acid as a preferred IV option for patients who cannot tolerate oral agents or at very high fracture risk on long-term glucocorticoids [10]. A randomized controlled trial (N=833) published in the New England Journal of Medicine demonstrated that zoledronic acid was superior to risedronate in preventing vertebral fractures in glucocorticoid-treated patients over 12 months [11].

Romosozumab in GIOP

Romosozumab's anabolic action makes it theoretically attractive in GIOP because it addresses the formation deficit directly, not just resorption. The ACR 2022 guidelines list romosozumab as an option for patients at very high fracture risk on glucocorticoids, though the evidence base is thinner than for bisphosphonates [10]. A phase 2 trial (N=139) showed romosozumab increased lumbar spine BMD by 16.3% in glucocorticoid-treated patients at 12 months versus 3.7% for alendronate [12]. No large fracture endpoint trial in GIOP for romosozumab exists yet.

GIOP Treatment Selection Framework (HealthRX Medical Team)

| Patient Profile | Preferred Agent | Rationale | |---|---|---| | GIOP, high risk, no CV disease, tolerates oral | Oral bisphosphonate first | Cost, safety data volume | | GIOP, very high risk, cannot tolerate oral | Zoledronic acid IV | ACR 2022 preferred IV option | | GIOP, very high risk, rapid bone loss, no CV disease | Romosozumab | Anabolic action targets formation deficit | | GIOP + prior CV event <12 months | Zoledronic acid or denosumab | Romosozumab boxed warning applies |

Chronic Kidney Disease (CKD)

Renal function is the single biggest practical differentiator between these two drugs in clinical settings.

Zoledronic Acid and CKD

The FDA prescribing information for zoledronic acid (Reclast) contraindicates use when creatinine clearance falls below 35 mL/min [13]. Zoledronic acid is renally cleared, and impaired excretion increases the risk of nephrotoxicity, hypocalcemia, and prolonged drug retention. Pre-infusion hydration and renal function monitoring are mandatory.

Romosozumab and CKD

Romosozumab is not renally cleared to the same extent. The FDA label does not impose an absolute CrCl cutoff, but warns that patients with CrCl <30 mL/min were excluded from major trials, so data are limited [2]. A small prospective cohort (N=62) published in Nephrology Dialysis Transplantation showed that romosozumab produced 7.4% lumbar spine BMD gains at 12 months in CKD stage 3b, 4 patients, with no significant worsening of renal function markers [14]. Hypocalcemia monitoring remains essential in CKD patients on either agent, given the calcium demands of anabolic bone formation.

Practical CKD guidance: For CKD stage 3a, 3b (CrCl 30 to 59 mL/min), zoledronic acid is usually still usable with dose-interval adjustment and close renal monitoring. For CKD stage 4 (CrCl 15 to 29 mL/min), romosozumab with close calcium monitoring may be the better-tolerated option pending individual assessment [15].

Prior Vertebral Fracture: Where Romosozumab Has the Strongest Data

Patients who have already sustained a vertebral fracture represent the population where romosozumab's ARCH data are most directly applicable.

The ARCH trial specifically enrolled women with at least one prior vertebral fracture (mean 1.4 fractures at baseline) [3]. The 48% reduction in new vertebral fractures over 24 months (romosozumab-then-alendronate versus alendronate alone) reflects a population that had already failed or was at elevated risk on antiresorptive monotherapy.

By contrast, HORIZON-PFT's vertebral fracture reduction of 70% was measured against placebo, a more favorable comparison denominator [1]. When both drugs are compared against active antiresorptive therapy in network meta-analyses, romosozumab's advantage narrows but persists for vertebral outcomes in very high-risk patients [4].

For a patient presenting with a recent vertebral fracture and no contraindications to romosozumab, initiating romosozumab followed by consolidation with zoledronic acid represents the sequence with the strongest supporting data.

Switching from Reclast (Zoledronic Acid) to Evenity (Romosozumab)

Should I switch from Reclast to Evenity? This question is one of the most common in osteoporosis specialty practice. The answer depends on whether the patient has adequate fracture risk justification and no cardiovascular contraindication.

When Switching Makes Sense

Switching from zoledronic acid to romosozumab is appropriate when a patient sustains a new fragility fracture while on zoledronic acid, when T-score remains below negative 2.5 after 3 years of therapy, or when the patient meets AACE very-high-risk criteria that were not present at treatment initiation [5].

The OPEN-ARCH observational study (N=309) documented real-world patients transitioning from prior bisphosphonate therapy (including zoledronic acid) to romosozumab. Lumbar spine BMD increased 9.4% at 12 months in bisphosphonate-pretreated patients, compared with 13.2% in treatment-naive patients, confirming that prior bisphosphonate use attenuates but does not eliminate the anabolic response to romosozumab [16].

When Switching Is Contraindicated or Inadvisable

Romosozumab carries an FDA black box warning: "Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" [2]. Any patient with recent acute coronary syndrome, stroke, or transient ischemic attack within 12 months must remain on zoledronic acid or an alternative without the cardiovascular signal.

Patients with adequate response to zoledronic acid (stable BMD, no new fractures) have no clinical indication to switch simply because romosozumab exists. The additional cost and injection burden are not justified in stable responders.

Sequencing After Romosozumab

After completing 12 months of romosozumab, sequential antiresorptive therapy is mandatory to preserve BMD gains. Zoledronic acid is the most studied consolidating agent in this context. The ARCH extension data show that alendronate maintained most BMD gains post-romosozumab, and zoledronic acid's equivalent antiresorptive potency with annual dosing makes it a preferred choice for patients who can tolerate IV infusion [3].

A 2023 retrospective analysis (N=188) in Osteoporosis International found that patients transitioning from romosozumab to annual zoledronic acid maintained 92% of their achieved lumbar spine BMD gains at 24 months post-romosozumab, compared with 83% in those who delayed sequential therapy beyond 3 months [17].

Safety Profiles Compared

Acute Phase Reaction

Zoledronic acid produces an acute phase reaction (flu-like symptoms, fever, myalgia) in approximately 32% of first-time infusion patients [1]. This typically resolves within 3 days and is much less common with repeat infusions. Pre-medicating with acetaminophen 650 mg before and for 72 hours post-infusion reduces severity.

Romosozumab's most common adverse effects are injection site reactions (18.9%) and arthralgias (13.3%) based on ARCH trial data [3]. Hypersensitivity reactions occur rarely.

Osteonecrosis of the Jaw and Atypical Femur Fractures

Both drugs carry warnings for osteonecrosis of the jaw (ONJ) and atypical femur fractures (AFF), though the absolute incidence with romosozumab (limited to 12 months of use) is substantially lower than with long-term bisphosphonate therapy. ONJ incidence with zoledronic acid in osteoporosis (non-oncology) populations is estimated at 0.017 to 0.04% per year [18]. AFF risk rises with longer bisphosphonate duration, from roughly 1 to 2 per 100,000 person-years at 3 years to 78 per 100,000 person-years at 8 years [18].

Hypocalcemia

Both drugs can precipitate hypocalcemia. Calcium and vitamin D supplementation is required for both, typically calcium 1,000 to 1,200 mg daily and vitamin D 800 to 1,000 IU daily. Baseline 25-OH vitamin D should be above 20 ng/mL before initiating either agent [5].

Cost and Access Considerations

Zoledronic acid's generic availability since 2018 has made it one of the most cost-effective IV osteoporosis therapies available. A single annual infusion administered in an outpatient infusion center typically costs $150, $400 for the drug, with additional facility fees. Most Medicare Part B and commercial plans cover it.

Romosozumab costs approximately $1,800, $2,200 per monthly injection, or $21,600, $26,400 per year of treatment. Amgen's Evenity patient assistance program (PATHWAYS) covers eligible uninsured patients and provides co-pay support for commercially insured patients who meet income criteria. Prior authorization is standard, and insurers typically require documented T-score below negative 2.5 plus either a prior fracture or failed prior bisphosphonate therapy.

Clinical Decision Summary

The choice is not binary. These drugs occupy different positions on the osteoporosis treatment sequence.

For most newly diagnosed postmenopausal women at high fracture risk without prior fracture and without CV risk, zoledronic acid remains the evidence-supported first-line IV option [1, 5].

For patients at very high risk, defined by prior fracture, T-score below negative 3.0, or ongoing rapid bone loss, and without cardiovascular contraindication, romosozumab for 12 months followed by zoledronic acid consolidation provides the greatest fracture reduction with durable BMD gains [3, 5].

For men, CKD stage 3 to 4 patients, and GIOP populations, the evidence base for both drugs thins; however, the ACR and AACE guidelines provide population-specific guidance that should be applied individually [5, 10].

The AACE 2020 clinical practice guidelines state directly: "In patients at very high risk of fracture, an anabolic agent should be used as initial therapy followed by an antiresorptive agent to maintain gains" [5]. Zoledronic acid is the most studied antiresorptive for that consolidation role.